EPAM Systems (EPAM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Mar, 2026Executive summary
Annual Meeting scheduled for May 21, 2026, with virtual participation and voting options for shareholders.
2025 performance marked by strong growth in AI-native services, double-digit sequential revenue increases, and strategic investments in AI capabilities.
Leadership transition executed, with Balazs Fejes appointed CEO and Arkadiy Dobkin as Executive Chair.
Board and management confident in continued revenue growth and profitability, supported by innovation and global delivery platform.
Voting matters and shareholder proposals
Election of four Class II directors for one-year terms.
Approval of amendment to Certificate of Incorporation to allow shareholders with 25% ownership to call special meetings.
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Advisory vote on executive compensation (say-on-pay).
Approval of amendments to increase shares in the 2025 Long Term Incentive Plan (by 4,000,000 shares) and 2021 Employee Stock Purchase Plan (by 650,000 shares).
Advisory vote on a shareholder proposal to allow special meetings at a 10% threshold, which the Board recommends against.
Board of directors and corporate governance
Board consists of 11 members, with phased declassification to annual elections by 2028.
Nine of 11 directors are independent; all committees are composed solely of independent directors.
Board diversity includes 36% female directors and members born outside the US.
Recent governance enhancements: elimination of supermajority voting, adoption of majority voting, and robust stockholder engagement.
Lead Independent Director role established and separated from Executive Chair.
Latest events from EPAM Systems
- Accelerating as an AI-native leader, targeting 16%+ margins and $1.8B+ free cash flow by 2028.EPAM
Investor Day 202612 Mar 2026 - Strong 2025 growth and AI momentum support a robust 2026 outlook for revenue and EPS.EPAM
Q4 202519 Feb 2026 - Q2 revenue down 2% YoY; healthcare strong, margins lower, new $500M buyback approved.EPAM
Q2 20242 Feb 2026 - Q3 revenue and EPS rose, NEORIS acquisition expanded reach, and share buybacks accelerated.EPAM
Q3 202416 Jan 2026 - Q4 2024 delivered strong growth and 2025 guidance targets double-digit revenue gains.EPAM
Q4 202413 Dec 2025 - Board declassification, majority voting, and new incentive plan headline 2025 proxy.EPAM
Proxy Filing1 Dec 2025 - Proxy seeks approval for board declassification, majority voting, and new long-term incentive plan.EPAM
Proxy Filing1 Dec 2025 - Key votes include director elections, governance reforms, and executive pay approval.EPAM
Proxy Filing1 Dec 2025 - Leadership transition announced: Dobkin to Executive Chairman, Fejes to CEO in September 2025.EPAM
Proxy Filing1 Dec 2025